

1fw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: ZICHE1

In re Application of:)	Conf. No.: 5690
)	
Marina ZICHE et al)	Art Unit: 1653
)	
Appln. No.: 09/756,185)	Examiner: R. Mitra
)	
Filed: January 9, 2001)	Washington, D.C.
)	
For: COMPOUND B AS ANGIOGENIC)	January 25, 2005
AGENT IN COMBINATION WITH)	
HUMAN GROWTH FACTORS)	

COMMUNICATION

Honorable Commissioner for Patents
U.S. Patent and Trademark Office
Randolph Building, Mail Stop Amendments
401 Dulany Street
Alexandria, VA 22314

Sir:

We are in receipt of a communication from the Manager of the Publishing Division in the Office of Patent Publication, entitled "Priority Acknowledgement", in response to the paper filed November 29, 2004, entitled "Request for Priority" that forwarded a certified copy of the European patent application from which this application claims priority.

The communication from the PTO is a form letter with four boxes. Box two was checked, i.e., "Applicant's claim for priority, based on papers filed in parent Application Number

In re of Appln. No. 09/719,748

PCT/EP99/04605 submitted under 35 U.S.C. 119, is
acknowledged."


It is pointed out that the above-identified
application is a continuation of PCT/EP99/04605 and not a
national stage. Therefore, it is believed that Box One should
have been checked, i.e.: "Receipt is acknowledged of priority
papers submitted under 35 U.S.C. 119. The papers have been
placed of record in the file."


Please correct the record in this regard.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant(s)

By


Roger L. Browdy
Registration No. 25,618


Allen Yum
Reg. No. 37,971

RLB:rd
Telephone No.: (202) 628-5197
Facsimile No.: (202) 737-3528
G:\BN\S\Ser1\Zichel\PTO\Communication.doc